Merck & Co., Inc. is a global research-driven pharmaceutical company .International developer, manufacturer and distributor of pharmaceuticals. Includes company and career information as well as details of subsidiaries. Headquarters in Whitehouse .
World Pharma News – The safety of patients is of utmost importance .Merck is a global pharmaceutical and chemical company with total revenues of € 7.6 billion in 2008, a history that began in 1668, and a future shaped by 32800 employees in 59 countries. Its success is characterized by innovations from .
European Medicines Agency Recommends Suspension of Marketing .About Merck Serono Merck Serono is the division for innovative prescription pharmaceuticals of Merck, a global pharmaceutical and chemical group. Headquartered in Geneva, Switzerland, Merck Serono discovers, develops, manufactures and .
Biopartners GmbH has announced that it will request a re-assessment from the EMEA in support of its novel interferon beta-1a, Biferonex®, after receiving a negative opinion from the European Medicines Agency’s Committee on Medicinal Products for Human Use (CHMP). According to EMEA procedures Biopartners will continue their work to accomplish the registration of Biferonex. “We are convinced about the strength of our data based on the results of a Phase III trial. merck pharmaceutical
Immune-boosting effect of Pegasys provides patients with the chance for a clinical cure New data presented showed that, for the first time, doctors can predict which hepatitis B patients treated with Pegasys (peginterferon alfa-2a) have the highest chance to achieve a positive treatment outcome and even a clinical cure1,2. merck pharmaceutical
GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta-based, publicly traded biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced the first injections in its Phase 2a Human Clinical Vaccine Trial for its candidate HIV/AIDS vaccine. The trial, designated HVTN 205, is being conducted by the HIV Vaccine Trials Network (HVTN). merck pharmaceutical
Schering-Plough Corporation (NYSE: SGP) announced that it has responded to the U.S. Food and Drug Administration (FDA) complete response letter for SAPHRIS(TM) (asenapine) sublingual tablets, which was received in January 2009. SAPHRIS is under review for the acute treatment of schizophrenia in adults and for the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults as monotherapy. merck pharmaceutical
